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ABSTRACT
Introduction: Over recent years there has been
growing evidence of increased risk of mortality
associated with antipsychotic use in older
people with dementia. Although this concern
combined with limited evidence of efficacy has
informed guidelines restricting antipsychotic
prescription in this population, the use of
antipsycotics remains common. Many
published studies only report short-term
outcomes, are restricted to examining
mortality and stroke risk or have other
limitations. The aim of this study was to assess
adverse outcomes associated with the use of
antipsychotics in older people living with
dementia in Wales (UK).
Methods: This was a retrospective study of a
population-based dementia cohort using the
Welsh Secure Anonymised Information Linkage
databank. The prior event rate ratio (PERR) was
used to estimate the influence of exposure to
antipsychotic medication on acute cardiac
events, venous thromboembolism, stroke and
hip fracture, and adjusted Cox proportional
hazard models were used to compare all-cause
mortality.
Results: A total of 10,339 people aged C65
years were identified with newly diagnosed
dementia. After excluding those who did not
meet the inclusion criteria, 9674 people
remained in the main cohort of whom 3735
were exposed to antipsychotic medication. An
increased risk of a venous thromboembolic
episode [PERR 1.95, 95% confidence interval
(CI) 1.83–2.0], stroke (PERR 1.41, 95% CI
1.4–1.46) and hip fracture (PERR 1.62, 95% CI
1.59–1.65) was associated with antipsychotic
use. However, there was no long-term increased
mortality in people exposed to antipsychotics
(adjusted hazard ratio 1.06, 95% CI 0.99–1.13).
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Conclusions: The increase in adverse medical
events supports guidelines restricting
antipsychotic use in this population.
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INTRODUCTION
Therearecurrentlyapproximately700,000people
in the UK with dementia [1]. As well as cognitive
disturbances, people living with dementia also
commonly develop behavioural and
psychological symptoms (BPSD). Clinical
guidelines for BPSD emphasise managing
aetiological factors, and the use of behavioural
and psychological interventions [2]. However,
antipsychotic medications have often been
prescribed for BPSD despite evidence of limited
clinical improvement [3–8]. Over the past decade
concerns have been raised over the prescribing of
antipsychotics in people living with dementia,
with the UK Committee for the Safety of
Medicines (CSM) and the U.S. Food and Drug
Administration (FDA) issuing statements to this
effect in 2004 [9] and 2005 [10], respectively.
These concerns are supported bymeta-analyses of
randomised controlled trials (RCTs) [5, 7, 11] and
a large U.S. cohort study [12]. Reports and
guidelines for clinicians have subsequently
expressed the need for extreme caution in
prescribing antipsychotic medication to people
living with dementia [1, 2, 13, 14]. Despite this,
antipsychotics are still commonly used in clinical
practice in the UK in this patient group [15, 16].
The newer, ‘atypical’ antipsychotic drugs appear
to carry lower risk than conventional (typical)
antipsychotic agents and the highest risk is in the
first 1–3 months of treatment [17–19].
There are, however, issues concerning the
findings of increased risk of mortality and other
adverse health outcomes in people with
dementia prescribed antipsychotic medication.
Many of the published studies only report
short-term adverse outcomes, the trials are
often from highly selected populations,
control group selection in observational
studies is often inadequate and increased
mortality is not a universal finding [20–23].
The objective of our study was to perform a
large population-based retrospective
electronic-cohort study of older people living
with dementia using linked routine data,
examining the relationship between
antipsychotics and serious adverse outcomes.
METHOD
Data Source
The retrospective cohort of older people with
dementia for this study was drawn from the
Secure Anonymised Information Linkage (SAIL)
databank based at the Health Information
Research Unit (HIRU), Swansea University.
SAIL brings together and links the widest
possible range of anonymised routinely
collected person-based data held in health and
social care datasets in Wales (UK). A large
amount of preliminary work on
anonymisation methodologies to protect
privacy was undertaken to create the SAIL
system [24, 25]. SAIL uses a split-file approach
to anonymisation to overcome confidentiality
and disclosure issues. Within each routine
dataset held in the SAIL databank,
anonymised individuals are assigned a unique
linking field or ALF (Anonymised Linking
Field). These are generated by the NHS Wales
Information Service using the Matching
Algorithm for Consistent Results in
Anonymised Linkage with 99.85% accuracy
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[25]. ALFs are further encrypted within SAIL and
used to link de-identified individuals across
multiple datasets. The SAIL system represents a
valuable resource for health-related research
whilst complying with the requirements of
data protection legislation and confidentiality
guidelines. For a more detailed description of
SAIL see Jones et al. [26].
The particular datasets within the SAIL
databank utilised for this project were:
• National Health Service (NHS)
Administrative Register, which is a register
of all individuals registered with a Welsh
general practitioner (GP) or who have ever
had contact with the NHS;
• General Practice Primary Care attendance
and clinical information database for all
general practice interactions including
symptoms, investigations, diagnoses
including co-morbidities, prescribed
medication and referrals to secondary and
tertiary care. The GPD database covered
approximately 40% of the population of
Wales at the time of the study;
• Cause of death (Office of National Statistics
Public Health Mortality files);
• Patient Episode Dataset for Wales (PEDW),
which includes demographic and clinical
data on all inpatient and day-case
admissions in NHS Wales hospitals and all
Welsh residents treated in other UK
countries;
• Outpatient Dataset, a minimum dataset
listing all outpatient appointments,
including mental health services in NHS
Wales hospitals.
Study Cohort
The SAIL databank was interrogated using
structured query language (DB2 SQL) to create
a cohort of people registered to a SAIL supplying
GP practice and aged C57 years at the onset of
the study period (1 January 2003). From this
group, those with a new diagnosis of dementia
during the study period (1 January 2003 to 31
December 2011) and aged C65 years at
diagnosis were identified. The diagnosis of
dementia was taken from GP computer records
using NHS Read browser terminology. Read
codes are a coded thesaurus of clinical terms
which have been used in the NHS since 1985
and are still widely used in the primary care
sector. They are the standard clinical
terminology by which clinicians can record
patient findings and procedures. The Read
codes used to identify participants for the
cohort were determined by using READ
Version 2 (5-byte). This database was manually
reviewed and searched by the researchers to
identify all the possible codes that may have
been used to record a diagnosis of dementia
(Appendix). To ensure the list of codes was
complete as possible, we also checked our list
against codes for dementia used to identify
cases for the Quality and Outcomes Framework
(QOF READ codes v27 for 2013/2014 [27]) and
the updated Charlson Index [28]. Patients
entered the cohort at the date of diagnosis of
dementia and left on the date of death, date of
leaving a SAIL supplying a GP or the study end,
whichever was the sooner.
Exclusions from the cohort included people
who had a prior diagnosis of schizophrenia and
bipolar affective disorder (functional psychosis)
and individuals diagnosed with cancer within
one year date of death. These individuals were
again identified in a similar manner from the
GP Read Coding [Electronic Supplementary
Material (ESM) Tables S1–3]. The exclusion of
people with functional psychosis was due to the
fact that the antipsychotic prescription was
likely to be for the treatment of the
underlying psychotic illness, and the exclusion
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of cancer patients was because antipsychotics
are used commonly for a different clinical
indication, namely nausea in the context of
palliative care.
Exposure to Antipsychotic and Other
Psychotropic Medications
From linked and anonymised prescribing
records we then determined whether
participants in the cohort had received
antipsychotic medication. From the GP
database we collated all prescriptions of
antipsychotic medications, again determined
by NHS Read codes (ESM Table S20). The type
of medication was further divided into
conventional (typical) and newer atypical
antipsychotics. Because of the debate
concerning the status of sulpiride (historically
conventional but structurally related to newer
drugs), this drug was coded separately to allow
inclusion in either group. We also recorded
information on the prescription of other
psychotropic medications, in particular
hypnotics and anxiolytics (ESM Tables S21 and
S22). Within these groups data on
benzodiazepine prescriptions were reviewed
(ESM Table S23).
With regard to the prescriptions the date of
first prescription after dementia diagnosis was
recorded.
We divided the cohort into two groups: one
who had received a prescription for
antipsychotic medications and a comparison
who had not (Fig. 1).
Clinical Characteristics, Co-morbidity
and Outcomes
Data evaluated on all participants included in
the cohort were gender and age at diagnosis of
dementia. The following co-variants were also
determined from the database information:
cerebrovascular disease, ischaemic heart
disease, parkinsonism, hip fracture, venous
thromboembolic event, atrial fibrillation,
epilepsy and diabetes. These co-variants were
identified using NHS Read codes (ESM
Tables S4–11) and their occurrence or
non-occurrence prior to the onset of dementia
was recorded.
The primary outcome was a serious adverse
event, including death, cerebrovascular disease
(episode of stroke or transient ischaemic
attack), acute cardiac event, venous
thromboembolic events [deep vein thrombosis
(DVT) or pulmonary embolism (PE)] and hip
fracture.
Participants were followed for the duration
of the study, their time in the cohort, and
length of follow-up dependent on their date of
diagnosis of dementia. The outcomes were
determined by using anonymously linked
information on each participant in the cohort.
Adverse outcomes were recorded from GP data
based on NHS Read codes (ESM Supplementary
Tables S12, S14, S16, S18). This information was
combined with data from PEDW; diagnosis in
our study was based on ICD-10 codes (ESM
Supplementary Tables S13, S15, S17, S19). Data
on death was obtained from the Office of
National Statistics database and included
information on date and cause of death. The
Read and ICD10 codes were selected by
manually searching the relevant classification
lists. To ensure completeness of the included
Read codes and ICD-10 we again checked our
list against updated Charlson Index codes
[28, 29].
Statistical Analysis
Basic demographic characteristics and history of
medical co-morbidities were compared between
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people with and without exposure to
antipsychotic medication. Adjusted relative
risks of death were calculated with Cox’s
proportional hazard models. Risk was adjusted
for age, gender and co-morbidities at dementia
diagnosis (epilepsy, parkinsonism, atrial
fibrillation, history of thromboembolism,
diabetes, ischaemic heart disease,
cerebrovascular disease, and previous hip
fracture; Model 1). Further adjustment was
Anpsychoc groups
Convenonal anpsychoc 
only (including sulpiride)
N = 1513
Atypical anpsychoc only
N = 1687
Both convenonal and 
atypical anpsychoc 
N = 535
Split into those prescribed an anpychoc and  those not prescribed an anpsychoc
Anpsychoc 
N = 3735
No Anpsychoc
N =5939
Exclusions: 
Psychosis prior to study onset; cancer within 1 year of death
Exluded n= 665 
Main cohort N=9674
Idenfy those with a new diagnosis of demena aged 65and over at diagnosis during study period
N = 10339
Idenfy all those registered with a SAIL supplying GP aged 57+ on 01.01.2003.  This populaon has the potenal to turn 65 during the 
study period 01.01.2003 and 31.12.2011
N = 272718
Fig. 1 Assembly of study cohort of older people with dementia. SAIL Secure Anonymised Information Linkage database
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made for use of hypnotics, anxiolytics and
benzodiazepines (Model 2).
The prior event rate ratio (PERR) adjustment
method was used to estimate the effects of
exposure to antipsychotic medication on the
likelihood of experiencing the adverse medical
outcomes of acute cardiac event, venous
thromboembolism, stroke and hip fracture.
The time to first event over 12 months of
follow-up (incidence) was calculated from the
date of the first antipsychotic (follow-up for
12 months) and for the 12-month period prior
to the date of the first antipsychotic. For those
not given an antipsychotic, a random date was
chosen to calculate time to first event prior and
post this random date. The PERR is calculated
as:
PERR ¼ Rate ratio during post period
Rate ratio during prior period
:
Confidence intervals (CIs) were obtained by
bootstrapping. The method assumes that the
confounding effects are constant across the
prior and post exposure periods and that there
is no confounder by treatment interactions
[30, 31]. The PERR cannot be applied for
terminal events and so was used to examine
acute cardiac events, venous thromboembolism
(DVT and PE), stroke and hip fracture—but not
mortality.
All data were analysed using STATA version
12 [32].
Secondary Analyses
To explore whether particular types of dementia
had different risk profiles we performed a
sub-group analysis examining outcomes for
people suffering from the main type of
dementia, Alzheimer’s disease (AD). Secondary
analyses also included a comparison of
outcomes in people receiving newer atypical
antipsychotics and those receiving
conventional antipsychotic medication.
Adjusted hazard ratios (HRs) were calculated
for both models. Additionally, we examined
mortality rates in 100-day blocks following
initial antipsychotic prescription.
Additional Sensitivity Analyses
We conducted two additional analyses to
further examine mortality risk differences:
1. Excluding people with contact with
specialist services in old age psychiatry.
This was performed in the case that
antipsychotic medication had been
prescribed in a secondary care setting that
would not have been identified in the
primary care database. It is possible that
antipsychotic medication could be
prescribed by specialist services in an
emergency situation or at the
commencement of treatment in an
out-patient consultation.
2. To determine whether the exclusion of
people with a diagnosis of cancer within 1
year of death influenced the results, we
repeated the main analysis by including
these people.
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors. Ethical approval was granted
from the HIRU Information Governance Review
Panel, an independent body consisting of a
range of government, regulatory and
professional agencies which oversees study
approvals in line with permissions already
granted to the analysis of data in the SAIL
databank [24, 25].
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The results are reported in accordance with
the STROBE checklist (http://www.epidem.
com/).
RESULTS
Cohort Characteristics
From 2003 until 2011 there were 272,718
people registered with a SAIL supplying GP in
Wales who were or had the potential to turn
65 years of age during the study period. From
these we identified 10,339 people with a new
diagnosis of dementia aged C65 years at
diagnosis. A total of 665 were excluded
because of pre-existing functional psychosis or
a diagnosis of cancer within 1 year of death,
leaving a total of 9674 people with dementia
forming the main cohort. Within this main
cohort, 3735 were exposed to antipsychotic
medication, and 5939 did not receive any
antipsychotics from their GP following their
dementia diagnosis. Figure 1 provides a
summary of the dementia e-cohort assembly
process.
The demographic characteristics and
baseline medical co-morbidities of older
people with dementia exposed and not
exposed to antipsychotic medications were
remarkably similar (Table 1). The exceptions to
this were a small difference in gender, with
males more likely to receive antipsychotics, and
a higher proportion of people in the
non-exposed group suffering from diabetes
before dementia diagnosis. There were high
rates of baseline co-morbidity, particularly
ischaemic heart disease and cerebrovascular
disease. The median follow-up period (until
death, leaving a SAIL supplying GP, or end of
study period) was 1.8 [interquartile range (IQR)
0.8–3.3] years in the main dementia cohort, 2.2
(IQR 1.1–3.8) years in the group exposed to
antipsychotic medication and 1.5 (IQR 0.6–3.0)
years in those not exposed to antipsychotics.
Antipsychotic Exposure, Mortality
and Other Main Outcomes
Older people with dementia exposed to
antipsychotic medication did not have an
increased risk of mortality compared to
non-exposed people when adjustment was
made for age at dementia diagnosis, gender or
baseline co-morbidity (Model 1) or after
adjusting for age at dementia diagnosis,
gender, baseline co-morbidity and exposure to
anxiolytic and/or hypnotic medication (Model
2) (Table 2). However, PERR analysis showed a
greater likelihood of increased venous
thromboembolism (DVT and PE), stroke and
hip fracture, but not acute cardiac event, in
those receiving antipsychotic medication
(Table 3).
Secondary Analyses
There were 6996 people with a diagnosis of
Alzheimer-type dementia, representing 72% of
those within the main dementia cohort.
Vascular dementia was the other main
dementia subtype (n = 2333; 24%), followed
by Lewy Body dementia (n = 139, 1.4%) and
mixed dementia (n = 132, 1.4%). There were no
significant differences in the proportions of
people in different dementia subtype groups
receiving antipsychotic medication (Chi-square
2.66(4), two-tailed P = 0.62). In both models of
adjustment, people with AD exposed to
antipsychotic drugs had no higher mortality
risk than non-exposed individuals (Table 2).
However, PERR analysis showed a greater
likelihood of acute cardiac event, venous
thromboembolism, stroke and hip fracture in
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those receiving antipsychotic medication
(Table 3).
There were 3735 (39%) people exposed to
antipsychotic medication in the main dementia
cohort, of whom 1687 received an atypical
antipsychotic medication, 1495 receive a
conventional antipsychotic drug, 535 were
exposed to both an atypical and conventional
antipsychotic and 18 were exposed to sulpiride
alone. The adjusted mortality HRs indicated no
significant differences between those receiving
conventional and atypical antipsychotics when
people exposed to both were excluded (Model 1:
adjusted HR 0.95, 95% CI 0.87–1.03; Model 2:
adjusted HR 0.94, 95% CI 0.86–1.03). In this
analysis, sulpiride was included as a
conventional antipsychotic, but there was also
no significant difference if sulpiride was
classified as an atypical one. Interestingly,
people with dementia receiving atypical
antipsychotics had a higher risk of acute
cardiac events following drug exposure than
those receiving conventional antipsychotics
(PERR 3.3, 95% CI 3.0–5.1), although the rates
of pre-exposure were lower. Stroke risk was
marginally lower in patients receiving atypical
compared to conventional antipsychotics (PERR
0.82, 95% CI 0.8–0.9).
When we examined mortality rates for
100-day blocks following the commencement
of antipsychoticmedication, the ratewashighest
in thefirst 100 days—11.5 (95%CI10.4–12.7) per
100 people per 100 days. This was a significantly
higher rate than that for the 301- to 400-day
block (8.7, 95% CI 7.6–10.1). The rates for the
intervening periods, namely 101–200 days and
201–300 days,were 9.4 (95%CI8.4–10.7) and9.3
(95% CI 8.2–10.5), respectively.
Table 1 General characteristics of dementia cohort by antipsychotic use
General characteristics of
study cohort
Exposed to antipsychotic
medication (n5 3735)
Not exposed to antipsychotic
medication (n5 5939)
% Difference
(95% CI)
Female 66.2% (2474) 67.8% (4025) 1.5* (0–3.4)
Mean age at diagnosis of
dementia (years)
82.4 (6.8) 82.5 (6.8) 0.1 (-0.1 to 0.4)
History of
Epilepsy 2.7% (99) 2.3% (138) 0.3 (-0.3 to 1.0)
Parkinsonism 4.0% (149) 3.7% (222) 0.25 (-0.5 to 1.1)
Atrial fibrillation 14.6% (546) 15.4% (914) 0.7 (-2.2 to 0.7)
Venous
thromboembolism
5.8% (217) 5.5% (329) 0.27 (-0.6 to 1.2)
Diabetes 13.7% (511) 15.8% (941) 2.2* (0.7–3.6)
Ischaemic heart disease 23.9% (893) 23.2% (1377) 0.7 (-1.0 to 2.5)
Cerebrovascular disease 22.3% (832) 22.5% (1338) 0.25 (-2.0 to 1.5)
Hip fracture 6.5% (243) 6.1% (364) 0.4 (-0.6 to 1.4)
* Significant difference between the group exposed to antipsychotic medication and the group not exposed
Values in table are presented as the percentage with the number (of people) in parenthesis, with the exception of Mean age
at diagnosis which is presented as the mean age with the standard deviation in parenthesis
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Table 3 Adverse event hazard ratio and adjusted prior event rate ratios by exposure to antipsychotic medication
Adverse event Exposed to antipsychotic Not exposed to antipsychotic Hazard ratio PERR (95% CI)
Acute cardiac event
All-cause dementia
Before
N per 1000 5.9 (22/3721) 7.1 (42/5908) 0.83
95% CI 3.9–9.0 5.2–9.6
After
N per 1000 12.4 (46/3720) 15.1 (89/5908) 0.82 0.98 (1.0–1.0)
95% CI 9.2–16.6 12.2–18.6
Alzheimer’s
Before
N per 1000 5.2 (14/2690) 9.6 (41/4270) 0.54
95% CI 3.1–8.8 7.0–13.0
After
N per 1000 11.1 (30/2680) 12.4 (53/4260) 0.89 1.65* (1.59–1.86)
95% CI 7.8–16.0 9.5–16.2
Known to primary care only
Before
N per 1000 5.5 (9/1642) 8.5 (29/3419) 0.64
95% CI 2.9–10.5 5.8–12.2
After
N per 1000 14.1 (23/1634) 12.9 (44/3408) 1.08 1.68* (1.05–1.78)
5% CI 9.3-21.1 9.6-17.3
Venous thromboembolism
All-cause dementia
Before
N per 1000 6.4 (24/3717) 6.7 (40/5909) 0.96
95% CI 4.3–9.6 5.0–9.2
After
N per 1000 13.0 (48/3705) 6.9 (41/5914) 1.88 1.95* (1.83–2.0)
95% CI 9.8–17.2 5.1–9.4
Alzheimer’s
Before
N per 1000 7.0 (19/2684) 6.5 (28/4276) 1.0
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Table 3 continued
Adverse event Exposed to antipsychotic Not exposed to antipsychotic Hazard ratio PERR (95% CI)
95% CI 4.5-11.0 5.0-9.2
After
N per 1000 14.2 (38/2674) 7.7 (33/4274) 1.8 1.80* (1.67–1.89)
95% CI 10.3-19.5 5.4-10.8
Known to primary care only
Before
N per 1000 6.7 (11/1639) 9.6 (33/3416) 0.7
95% CI 0.3–12.1 5.0–9.2
After
N per 1000 14.1 (23/1632) 7.6 (26/3422) 1.85 2.66* (2.41–2.78)
95% CI 9.3–21.2 5.2–11.1
Stroke
All-cause dementia
Before
N per 1000 35.0 (128/3652) 37.8 (219/5789) 0.92
95% CI 29.4–41.6 33.1–43.1
After
N per 1000 65.8 (236/3587) 50.8 (292/5749) 1.3 1.41* (1.40–1.46)
95% CI 57.9–74.7 45.2–57.0
Alzheimer’s
Before
N per 1000 25.6 (68/2653) 34.0 (143/4207) 0.75
95% CI 20.2–32.4 28.8–40.0
After
N per 1000 61.1 (159/2601) 39.6 (166/4190) 1.54 2.06* (1.97–2.13)
95% CI 52.3–71.4 34.0–46.1
Known to primary care only
Before
N per 1000 41.9 (67/1599) 50.2 (167/3327) 0.83
95% CI 32.9–53.2 43.1–58.4
After
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Sensitivity Analyses
When we excluded patients with a known
contact with secondary care specialist mental
health services for older people (outpatient and
community team), the main cohort was
reduced substantially from 9674 to 5089
people with dementia. Adjusted mortality HRs
Table 3 continued
Adverse event Exposed to antipsychotic Not exposed to antipsychotic Hazard ratio PERR (95% CI)
N per 1000 70.2 (111/1581) 48.6 (162/3330) 1.44 1.73* (1.66–1.75)
95% CI 58.2–84.5 41.7–56.7
Hip fracture
All-cause dementia
Before
N per 1000 24.4 (90/3679) 24.5 (143/5842) 1.0
95% CI 19.9-30.1 20.8-28.8
After
N per 1000 55 (200/3617) 34.2 (199/5817) 1.61 1.62* (1.59–1.65)
95% CI 47.9–63.2 29.8-39.3
Alzheimer’s
Before
N per 1000 27.1 (72/2653) 25.3 (107/4226) 1.07
95% CI 21.5–34.2 20.9–30.6
After
N per 1000 59.0 (154/2608) 33.4 (141/4213) 1.76 1.65* (1.61–1.71)
95% CI 50.4–69.1 28.3–39.4
Known to primary care only
Before
N per 1000 25.2 (41/1623) 22.4 (76/3390) 1.13
95% CI 18.5–34.3 17.9–28.1
After
N per 1000 57.1 (91/1593) 32.3 (109/3369) 1.76 1.57* (1.52–1.65)
95% CI 46.5–70.1 26.8–39.0
* Significantly higher likelihood of acute cardiac event, venous thromboembolism, stroke and hip fracture in those receiving
antipsychotic medication
PERR Prior event rate ratio
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(both Model 1 and 2) showed no differences
between those exposed and not exposed to
antipsychotic medication (Table 2). The PERR
analysis showed a raised risk of acute cardiac
event, venous thromboembolism, stroke and
hip fracture for people with dementia receiving
antipsychotics compared to non-exposed
patients (Table 3).
When we included people with cancer
within 1 year of death in the dementia cohort,
the adjusted mortality HR was still
non-significant (Model 1: HR 0.97, 95% CI
0.92–1.02).
DISCUSSION
Summary of Main Findings
The most important finding in our study was
the increased likelihood of venous
thromboembolism, stroke and hip fracture in
older people living with dementia who were
exposed to antipsychotic medication. The
findings for people living with AD mirrored
those for people living all-cause dementia, but
the former had an additional increased risk of
an acute cardiac event.
Surprisingly, there was no overall increased
risk of death for older people living with
dementia exposed to antipsychotic medication
compared to non-exposed individuals although
the mortality was comparatively high during
the first 100 days of treatment with an
antipsychotic and subsided thereafter. The
absence of increased long-term mortality risk
needs to be viewed with caution in view of a
number of methodological limitations outlined
below, including the absence of data on the
duration of treatment. Interestingly, there was
no difference in the risk of death between
people receiving atypical and conventional
antipsychotics.
The main study was conducted on 9674 older
people (aged 65 years and over) with dementia
in the region of Wales in the UK; this would
include people living in their own homes as well
as in residential and nursing homes.
Results in Context
Our finding of a comparatively high mortality
in the first 100 days after the initiation of
antipsychotic treatment in older people with
dementia is consistent with the body of
literature describing the short-term increased
mortality associated with antipsychotic use in
dementia [11, 12, 33]. However, the absence of
any overall long-term increased risk of mortality
associated with exposure to antipsychotic
medication requires a more detailed
consideration. The first factor is that other
studies which have examined longer-term
effects of antipsychotics have similarly found
no increased risk [22, 23]; in particular, Lopez
et al. [22] showed that it was the presence of
BPSD that was associated with the increased risk
of mortality. Secondly, our cohort study
occurred later than previously published
studies, and most of the cohort period is after
the publication of the CSM [9] and FDA [10]
guidances; this may have resulted in more
careful prescribing [34, 35], although the rates
of ischaemic heart disease were similar in both
exposed and non-exposed groups. Thirdly, our
cohort has a relatively high mean age and is
population based rather than a selected sample
as utilised for some other cohort studies
[12, 19]. Additionally, we have high rates of
medical co-morbidity—almost double the rate
of pre-existing cerebrovascular and significant
cardiac disease compared to a large Canadian
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cohort study [33]. Clearly many of our cohort
members would not have satisfied the stringent
selection criteria for recruitment into a RCT for
the treatment of BPSD in dementia. Also there
may be a survival effect, as well as the possible
role of improved aftercare compared to previous
studies; there are comprehensive community
services in Wales (UK) for older people with
dementia, including in-reach to care homes
[36]. One further explanation for a lack of
overall increased mortality associated with
antipsychotic use derives from studies that
include measures of psychotic symptoms and
agitation—when controlling for these factors
the risk of mortality was not increased [20, 22],
and this could be accounted for by the use of
restraint in people not receiving medication
[20]. However, there are also a number of
methodological limitations that could account
for the absence of increased long-term mortality
associated with antipsychotics. In particular,
the lack of duration of treatment with
antipsychotics is an important consideration,
as some people may have received a short-term
prescription only. This could well be the case for
an episode of delirium in the context of
dementia. The finding that mortality was
relatively high in the first 100 days following
initiation of treatment and then subsided could
be explained by a short duration of treatment.
Secondly, stratification into groups of exposed
and non-exposed to antipsychotic medication,
respectively, for the Cox’s proportional hazard
mortality analysis occurred following the
diagnosis of dementia and was not time
dependent (unlike for the PERR adjustment
method); consequently, some people living
with dementia for that particular analysis may
be included in the exposed group despite
having a significant period of non-exposure.
Besides examining mortality, other research
into adverse outcomes in antipsychotic use in
older people with dementia has focused on falls
and stroke [13, 37]. Our findings of both an
increased risk of hip fracture and stroke are
consistent with the results of these previous
studies. Our study utilised both hospital
discharge data and primary care records to
identify cerebrovascular adverse events,
reducing the likelihood of more minor events
in the community (such as transient ischaemic
attack) or more terminal events managed in a
care home setting being missed.
The risk of acute cardiac events as a
consequence of antipsychotic use in older
people with dementia has not been previously
examined in detail [5, 6, 8], but there is an
expectation of increased in risk based on drug
trial data and the findings of electrocardiogram
abnormalities in younger populations [38]. We
had high levels of pre-existing ischaemic heart
disease in our dementia cohort and found an
increased risk of acute cardiac event in people
living with AD who were exposed to
antipsychotics, those living with dementia
who received antipsychotics and were known
only to primary care and those receiving
atypical antipsychotic drugs compared to
those receiving conventional ones. However,
events were relatively few compared to other
outcomes, in particular pre-treatment in those
exposed to antipsychotic medication (especially
atypicals). The higher risk associated with
atypical compared to conventional
antipsychotic medication may be explained by
clinicians selecting one drug over another in ‘at
risk’ patients; when prior events influence the
probability of drug use, then bias may occur
when using the PERR method [30].
An increased risk of venous
thromboembolism associated with
antipsychotic medication has previously been
reported in an UK population-based nested
case–control study, with older people at
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particular risk [39], and also in older people
with dementia in a German nested case–control
study [40]. Our study supports this finding in
older people with dementia; inactivity-related
venous stasis may not be the only mechanism
involved—enhanced platelet aggregation and
raised anticardiolipin antibodies may also be
important factors [41].
Conventional antipsychotic agents have
generally been found to be associated with a
greater risk of mortality compared to newer
atypical drugs [12, 17–19, 33, 42–45], but there
are some exceptions [20, 22]. We found no
difference between conventional and atypical
antipsychotic drugs for mortality or any other
adverse outcomes regardless of how sulpiride
was categorised. This could be explained by
some of the reasons previously outlined; in
particular, the fact that our cohort is more
recent. Studies based on Medicare and Medicaid
primarily compared atypical drugs with
haloperidol; the latter had often been
prescribed in relatively high dosages for this
frail client group [18, 42]. Other studies have
failed to adequately consider the potential
confounding effect of prescribing relatively
high-dose typical antipsychotics for patients
receiving palliative cancer care [19, 33, 43].
Strengths and Limitations
This is the first large, long-term UK population
based study of adverse outcomes associated with
exposure to antipsychotics in older people with
dementia. In utilising the SAIL databankwewere
able to assess baseline co-morbidity and identify
adverse outcomes from both hospital in-patient
episodes and primary care records, thereby
reducing the possibility of missing adverse
events. Additionally, we are able to include all
dementia subtypes and not restrict our study to
AD. Although the detection of dementia rate in
Wales in 2015 was 43.4%, this estimated rate is
based on figures utilising the basic Read codes
used in the NHS QOF data [46]. Our study
pre-dates the use of these codes for QOF in
Wales, andoneof the strengths of the study is the
broader use of diagnostic codes to identify
dementia. The dementia Read codes used in our
study are similar to those used in research based
upon the Clinical Practice Research Datalink in
England; they have been found to have positive
predictive value of 80–90% [47] and have high
levels of agreement with Hospital Episode
Statistics data [48]. Our case identification is
therefore sufficiently reliable for a study of this
nature, particularly as we were primarily
interested in the effects of antipsychotic
prescribing in patients known to have dementia
in the primary care setting. Additionally, our
cohort is generally from a later period than
comparable studies—2003–2011 and
predominantly after publication of the CSM
and FDA guidances. Other strengths are our
broad use of diagnostic codes, ability to control
for effects of other psychotropic use and our
careful exclusion criteria. Older people with
pre-existing dementia are particularly
vulnerable to experiencing concurrent delirium
when physically unwell, and the lack of data on
co-morbid delirium could be relevant for the
Cox’s mortality HR analyses. Unfortunately,
delirium is poorly recorded in general practice
[49], and so it is difficult to control for this factor.
However,we chose theadjustedPERRmethod for
non-fatal adverse outcomes as it can reduce bias
as a consequence of unmeasured confounding
[30, 50]. Additionally, as we were examining
antipsychotic prescribing in general practice and
subsequent serious adverse outcomes in relation
to conditions that frequently lead to
hospitalisation, it is unlikely that co-morbid
delirium at the time of index prescribing
significantly influenced our findings.
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There are limitations to the data available
within the SAIL databank, namely the lack of
information on individual drug frequency and
the duration of prescription. The influence of
these two factors has been discussed previously,
as well as the limitations of the Cox
proportional hazard analysis for mortality risk.
Another deficiency is the absence of prescribing
data for secondary care. However, in our
sensitivity analyses we excluded patients
known to older peoples’ mental health
services, and the findings remained relatively
consistent. There remains the possibility that a
small number of people may have had a
hospital in-patient episode when they were
exposed to an antipsychotic for a short period,
and this was not continued on discharge from
hospital, or an antipsychotic could have been
prescribed for BPSD before the dementia
diagnosis was formally noted in the patient’s
records. Another limitation associated with the
use of linked routine data is the inability to
consider the influence of degree of functional
and cognitive impairment or the presence and
severity of BPSD.
CONCLUSION
Although there are only limited effects on
behavioural and psychological symptoms with
antipsychotic medications in older people with
dementia, they continue to be used despite
concerns over their safety [5]. Guidelines stress
the importance of managing contributing
medical co-morbidity, as well as the use of
environmental, psychological and behavioural
treatment strategies [2]. Although evidence for
non-pharmacological interventions is
increasing [51, 52], the availability and
implementation of these interventions remain
restricted by resources, and additionally the
evidence for their efficacy still requires further
evaluation [18].
Our study shows that there is a clear
increased risk of adverse medical outcomes, in
particular venous thromboembolism (DVT and
PE), stroke and hip fracture in older people
living with dementia who are exposed to
antipsychotic medications. This risk supports
recommendations restricting non-emergency
antipsychotic medication use in people with
dementia to those with psychosis or severe
aggression when other non-pharmacological
treatment strategies have failed [52–54].
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APPENDIX 1
See Table 4.
Table 4 Read codes for dementia
Senile dementia E00..
Senile/pre-senile dementia E00..
Uncomplicated senile dementia E000.
Pre-senile dementia E001.
Uncomplicated pre-senile dementia E0010
Pre-senile dementia with delirium E0011
Pre-senile dementia with paranoia E0012
Pre-senile dementia with depression E0013
Pre-senile dementia NOS E001z
Senile dementia with depressive or paranoid
features
E002.
Senile dementia with paranoia E0020
Senile dementia with depression E0021
Senile dementia with depressive or paranoid
features
E002z
Senile dementia with delirium E003.
Arteriosclerotic dementia E004.
Multi-infarct dementia E004.
Uncomplicated arteriosclerotic dementia E0040
Arteriosclerotic dementia with delirium E0041
Arteriosclerotic dementia with paranoia E0042
Arteriosclerotic dementia with depression E0043
Arteriosclerotic dementia NOS E004z
Other alcoholic dementia E012.
Chronic alcoholic brain syndrome E0120
Dementia in conditions EC E041.
[X]Dementia in Alzheimer’s disease Eu00.
[X]Dementia in Alzheimer’s disease with early
onset
Eu000
[X]Pre-senile dementia, Alzheimer’s type Eu000
[X]Primary degenerative dementia, Alzheimer’s
type, pre-senile onset
Eu000
[X]Dementia in Alzheimer’s disease with late
onset
Eu001
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